Titan Pharmaceuticals Inc

Titan Pharmaceuticals — Investor Presentation (December 2019)

24 slides from Titan Pharmaceuticals's investor presentation, Dec 10, 2019

  1. Slide 1: Titan Corporate Presentation | December 2019

    Titan Pharmaceuticals Titan Corporate Presentation | December 2019 Company Confidential | Do Not Copy or Distribute | Copyright © Titan Pharmaceuticals 2019

  2. Slide 2: Forward-looking statements

    This presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, or the Securities Act, and Section 21 E of the Securities Exchange Act of 1934 , or the Exchange Act . All statements other than statements of historical facts conta

  3. Slide 3: Highlights

    Highlights 3 Innovative & Proprietary Drug Delivery Platform Refocused Commercialization Strategy Large & Growing Market Opportunity Experienced Management Team

  4. Slide 4: ProNeura Long-Term Drug Delivery Platform

    Plasma Drug Levels Time Therapeutic Window ProNeura Oral Delivery Titan’s Proprietary Technology ProNeura™ Long - Term Drug Delivery Platform 4 Drug is released continuously into patient's body through diffusion controlled dissolution • Provides continuous delivery of medication into the sub - derma

  5. Slide 5: Marketing Probuphine for Opioid Use Disorder

    Marketing Probuphine ® (buprenorphine) implant for the maintenance treatment of Opioid Use Disorder (OUD) in clinically stable patients on 8 mg or less a day of oral buprenorphine Transitioned to a Commercial - Stage Company First Approved ProNeura - Based Product 5 * European patent was acquired by

  6. Slide 6: Addiction To Opioids Challenge & Opportunity

    Addiction To Opioids Challenge & Opportunity Approximate U.S. annual sales 1 Buprenorphine is the gold standard in Medication Assisted Therapy (MAT) $2B U.S. Opioid Overdose Deaths in 2017 3 Each Day 3 130 From Prescription Opioids 4 35% As many as in 1999 3 6X Challenges with sublingual buprenorphi

  7. Slide 7: Market Opportunity

    Market Opportunity Unsatisfied Growing Market 7 50% of the patient population with OUD is medically treated 1 Less Than 46,500 of physicians, representing 5% of the nation’s doctors , are currently certified to prescribe buprenorphine 2 Approximately 6,000 physicians are writing approximately 90% of

  8. Slide 8: Treatment Paradigm

    Treatment Paradigm 8 PROBUPHINE is the first and only implant that provides continuous 6 - month maintenance treatment of opioid use disorder in eligible patients 1 The World Health Organization has designated buprenorphine an essential medicine for the treatment of opioid use disorder 2 WARNING: IM

  9. Slide 9: ProNeura-Based Products & Product Candidates

    ProNeura - Based Products & Product Candidates Robust Addiction Pipeline 9 Nalmefene implant • Nalmefene is a full opioid antagonist in development for treatment of OUD by several companies (daily dosed formulations) • Titan was awarded a grant of $8.7 Million by National Institutes of Health (NIH –

  10. Slide 10: Probuphine U.S. Relaunch

    Probuphine U.S. Relaunch Building a Strong Foundation for Growth 10

  11. Slide 11: Probuphine Highlights Potential Differentiators

    Probuphine Highlights Potential Differentiators 11 Administered as a 6 - month implant, Probuphine does not require daily supervised use May help remove the stigma and stress of daily dispensing, helping patients and their families maintain a standard lifestyle of employment, relationships and caret

  12. Slide 12: Key Areas of Focus

    Key Areas of Focus Commenced Q4 2018 12 Market Access • Market segmentation • Specialty pharmacy distribution network • Patient services “hub” • 3 rd party payors Medical Information • Regulatory and compliance program • Healthcare provider training • Doctor and patient marketing Commercial Infrastr

  13. Slide 13: Key Specialty Pharmacies Added to Network

    Key Specialty Pharmacies (SPs) Added to Network National Coverage & Strong Relationships with 3 rd Party Payors 13 Announced February 2019: • Network of fulfillment sites spanning entire U.S. Announced May 2019: • Among top SP networks in U.S. Announced June 2019: • Large location in CA; numerous lo

  14. Slide 14: Streamlining the Distribution Process

    Streamlining the Distribution Process Shortening the Time from Prescription to Product Delivery 14 Physician receives the reimbursed product delivered (up to 3 months) Specialty pharmacy contacts physician to fill out the same application Insurance company contacts physician HUB contacts physician t

  15. Slide 15: Third Party Payor Update

    3 rd Party Payor Update Gaining Market Access 15 • Established a Medicaid Drug Rebate Agreement - Probuphine added to Medicaid for rebate coverage - Medicaid paid for $917 million of buprenorphine in 2018 1 - Medicaid covers nearly 40% of adults with an OUD 2 • Established Medicare Part B coverage w

  16. Slide 16: Building on Step Into Stability

    Building on STEP INTO STABILITY Expanding Demand with HCPs 16 Revised HCP Sales Aid New In - office Demo New HCP ePortal TitanProNet.com New HCP Portal Registration Form New Formulary Access State Specific

  17. Slide 17: Next Stages of Commercialization

    Next Stages of Commercialization 17

  18. Slide 18: Sales Growth Initiatives

    Sales Growth Initiatives New initiatives: • Expand reach and frequency with additional sales staff and/or co - promotional partnerships • Actively pursuing and engaging with key decision makers at residential treatment centers, VA clinics and the federal/state prison systems Ongoing initiatives: • C

  19. Slide 19: Patients with Potential Need for Long Acting Buprenorphine

    Patients with Potential Need for Long Acting Buprenorphine 356.8 568 449 63 31 28 68 11 23 80 1500 7032 4231 706 340 332 211 258 1719 330 Patients and Treatment Settings Probuphine Has Highest Potential Within Certain Settings 19 Facilities with High Need for Long Acting Buprenorphine (n=3,896) 1.Na

  20. Slide 20: Europe A Significant Opportunity

    Europe A Significant Opportunity 20 • Molteni Farmaceutici of Italy acquired Probuphine EU intellectual property from Titan and will commercialize the product in the EU and certain other territories • Sixmo (EU name for Probuphine ) is the first and only six months substitution treatment for opioid

  21. Slide 21: Probuphine Summary

    Probuphine Summary 21 Probuphine Only product on market to provide six - month, continuous blood levels of buprenorphine for maintenance treatment of OUD in eligible patients U.S. Commercialization Probuphine relaunch showing early signs of positive proof of concept; next step = expand outreach Part

  22. Slide 22: Experienced Management

    Experienced Management Executive Team & Board of Directors 22 Marc Rubin, M.D. Executive Chairman, Director Sunil Bhonsle , M.B.A. President & CEO, Director Kate DeVarney , Ph.D. Executive Vice President & Chief Scientific Officer Dane Hallberg Executive Vice President & Chief Commercial Officer Jos

  23. Slide 23: Investment Highlights

    Investment Highlights 23 Innovative & Proprietary Drug Delivery Platform Refocused Commercialization Strategy Large & Growing Market Opportunity Experienced Management Team

  24. Slide 24: Titan Pharmaceuticals

    Titan Pharmaceuticals Titan Corporate Presentation | December 2019 Company Confidential | Do Not Copy or Distribute | Copyright © Titan Pharmaceuticals 2019

Titan Pharmaceuticals — Investor Presentation (December 2019) on 6ix